我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

心肌细胞能量代谢调控研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第4期
页码:
473-476,485
栏目:
综述
出版日期:
2018-04-25

文章信息/Info

Title:
Progress in energy metabolism regulation of cardiomyocytes
作者:
封欣妤; 王善杰; 赵志敬; 孙冬冬
(第四军医大学西京医院心血管内科, 陕西 西安 710032)
Author(s):
FENG Xin-yu;  WANG Shan-jie;  ZHAO Zhi-jing;  SUN Dong-dong
(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
心肌细胞; 能量代谢; 心脏缺血; 糖尿病心肌病
Keywords:
cardiac myocytes;  Energy metabolism;  heart ischemia;  diabetic cardiomyopathy
分类号:
R333.6
DOI:
-
文献标识码:
A
摘要:
研究伴随物质代谢过程中能量的释放、转移、储存和利用已经有上百年历史。心脏是能量代谢相对活跃的器官，有研究表明每天心脏三磷酸腺苷（ATP）的转化量是其体质量的15~20倍。糖尿病心肌病、缺血性心肌病、肥厚性心肌病及扩张性心肌病等都与心肌细胞能量代谢紊乱息息相关，因此，研究心肌细胞能量代谢过程及其调控机制，对上述疾病的治疗具有重要的指导意义。近年仍然有不少学者在此方面进行了深入研究，本文对这些研究的结果做以总结，分别从底物的选择、糖代谢及脂代谢等方面进行综述。
Abstract:
Research on the release, transport, storage, and use of energy in the process of metabolism has been conducted for hundreds of years. The heart is relatively active among the energy metabolism organs and studies have shown that the daily conversion quantity of heart ATP is 15-20 times of its weight. Diabetic cardiomyopathy, ischemic cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and many other diseases are closely related to myocardial cell energy metabolism disorders. Research on myocardial cell energy metabolism and its regulation mechanism is of important guiding significance for the treatment of these diseases. In recent years, many scholars have conducted in-depth studies in this regard and this article summarizes findings from the choice of substrate, sugar metabolism, and lipid metabolism.

参考文献/References

[1]Neely JR,Rovetto MJ,Oram JF.Myocardial utilization of carbohydrate and lipids[J].Prog Cardiovasc Dis,1972,15(3):289-329.

[2]Mirtschink P,Krek W.Hypoxia-driven glycolytic and fructolytic metabolic programs:Pivotal to hypertrophic heart disease[J].Biochim Biophys Acta,2016,1863(7):1822-1828.

[3]Mcgill JB,Peterson LR,Herrero P,et al.Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance[J].J Nucl Cardiol,2011,18(3):421-429,432-433.

[4]Haffar T,Bérubé-Simard F,Bousette N.Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes[J].Biochem Biophys Res Commun,2015,468(1-2):73-78.

[5]Lei B,Lionetti V,Young ME,et al.Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure[J].J Mol Cell Cardiol,2004,36(4):567-576.

[6]Abel ED.Free fatty acid oxidation in insulin resistance and obesity[J].Heart Metab,2010,48:5-10.

[7]van den Brom CE,Bulte CS,Loer SA,et al.Diabetes,perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism[J].Cardiovasc Diabetol,2013,12:42.

[8]Taegtmeyer H.Glycogen in the heart--an expanded view[J].J Mol Cell Cardiol,2004,37(1):7-10.

[9]Szablewski L.Glucose transporters in healthy heart and in cardiac disease[J].Int J Cardiol,2017,230:70-75.

[10]Shao D,Tian R.Glucose Transporters in Cardiac Metabolism and Hypertrophy[J].Compr Physiol,2015,6(1):331-351.

[11]Banerjee SK,Mcgaffin KR,Pastor-Soler NM,et al.SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states[J].Cardiovasc Res,2009,84(1):111-118.

[12]Chanda D,Luiken JJ,Glatz JF.Signaling pathways involved in cardiac energy metabolism[J].FEBS Lett,2016,590(15):2364-2374.

[13]Cook SA,Varela-Carver A,Mongillo M,et al.Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction[J].Eur Heart J,2010,31(1):100-111.

[14]Zaha VG,Young LH.AMP-activated protein kinase regulation and biological actions in the heart[J].Circ Res,2012,111(6):800-814.

[15]Stanley WC.Myocardial Substrate Metabolism in the Normal and Failing Heart[J].Physiol Rev,2005,85(3):1093-1129.

[16]Marsin AS,Bertrand L,Rider MH,et al.Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia[J].Curr Biol,2000,10(20):1247-1255.

[17]Sung MM,Zordoky BN,Bujak AL,et al.AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism[J].Cardiovasc Res,2015,107(2):235-245.

[18]Schwenk RW,Luiken JJ,Bonen A,et al.Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease[J].Cardiovasc Res,2008,79(2):249-258.

[19]Coort SL,Bonen A,van der Vusse GJ,et al.Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters[J].Mol Cell Biochem,2007,299(1-2):5-18.

[20]Violante S,Ijlst L,Te BH,et al.Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines[J].FASEB J,2013,27(5):2039-2044.

[21]Kerner J,Hoppel C.Fatty acid import into mitochondria[J].Biochim Biophys Acta,2000,1486(1):1-17.

[22]Plutzky J.The PPAR-RXR Transcriptional Complex in the Vasculature:Energy in the Balance[J].Circ Res,2011,108(8):1002-1016.

[23]Barlaka E,Galatou E,Mellidis K,et al.Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart:Focus on the Nonmetabolic Effects in Cardiac Protection[J].Cardiovasc Ther,2016,34(1):37-48.

[24]Chen W,Wang LL,Liu HY,et al.Peroxisome proliferator-activated receptor delta-agonist,GW501516, ameliorates insulin resistance,improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice[J].Basic Clin Pharmacol Toxicol,2008,103(3):240-246.

[25]Mahajan UB,Chandrayan G,Patil CR,et al.The Protective Effect of Apigenin on Myocardial Injury in Diabetic Rats mediating Activation of the PPAR-gamma Pathway[J].Int J Mol Sci,2017,18(4).pii: E756.doi:10.3390/ijms18040756

[26]Tenenbaum A,Motro M,Fisman EZ,et al.Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease[J].Circulation,2004,109(18):2197-2202.

[27]Riserus U,Sprecher D,Johnson T,et al.Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men[J].Diabetes,2008,57(2):332-339.

[28]Barlaka E,Galatou E,Mellidis K,et al.Role of Pleiotropic Properties of Peroxisome Proliferator-Activated Receptors in the Heart:Focus on the Nonmetabolic Effects in Cardiac Protection[J].Cardiovasc Ther,2016,34(1):37-48.

[29]Gerhart-Hines Z,Rodgers JT,Bare O,et al.Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha[J].EMBO J,2007,26(7):1913-1923.

[30]Schenk S,Mccurdy CE,Philp A,et al.Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction[J].J Clin Invest,2011,121(11):4281-4288.

[31]Shi T,Fan GQ,Xiao SD.SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells[J].J Dig Dis,2010,11(1):55-62.

[32]Laurent G,German NJ,Saha AK,et al.SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase[J].Mol Cell,2013,50(5):686-698.

[33]Parihar P,Solanki I,Mansuri ML,et al.Mitochondrial sirtuins:emerging roles in metabolic regulations,energy homeostasis and diseases[J].Exp Gerontol,2015,61:130-141.

[34]Tuunanen H,Knuuti J.Metabolic remodelling in human heart failure[J].Cardiovasc Res,2011,90(2):251-257.

[35]Sugden MC,Langdown ML,Harris RA,et al.Expression and regulation of pyruvate dehydrogenase kinase isoforms in the developing rat heart and in adulthood: role of thyroid hormone status and lipid supply[J].Biochem J,2000,352(Pt 3):731-738.

[36]Sugden MC,Holness MJ.Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs[J].Am J Physiol Endocrinol Metab,2003,284(5):E855-E862.

[37]Hwang B,Jeoung NH,Harris RA.Pyruvate dehydrogenase kinase isoenzyme 4(PDHK4)deficiency attenuates the long-term negative effects of a high-saturated fat diet[J].Biochem J,2009,423(2):243-252.

[38]Mayers RM,Leighton B,Kilgour E.PDH kinase inhibitors:a novel therapy for Type II diabetes?[J].Biochem Soc Trans,2005,33(Pt 2):367-370.

[39]Ussher JR,Wang W,Gandhi M,et al.Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury[J].Cardiovasc Res,2012,94(2):359-369.

[40]Wheeler TJ,Chien S.Characterization of the high-affinity uptake of fructose-1,6-bisphosphate by cardiac myocytes[J].Mol Cell Biochem,2012,366(1-2):31-39.

[41]van Bilsen M,van der Vusse GJ,Reneman RS.Transcriptional regulation of metabolic processes: implications for cardiac metabolism[J].Pflugers Arch,1998,437(1):2-14.

备注/Memo

备注/Memo:
收稿日期：2017-05-09.通讯作者：孙冬冬，副教授，主要从事冠心病临床及基础研究Email:wintersun3@gmail.com 共同通讯作者：赵志敬, 副教授，主要从事冠心病机理及防治研究 Email：zhaozhj@fmmu.edu.cn 作者简介：封欣妤，住院医师 Email：852223297@qq.com
更新日期/Last Update: 1900-01-01